Osteoporosis

Primary osteoporosis is associated with postmenopausal estrogen deficiency and with age-related bone loss. The grounding also supports a broader model in which derangements in bone cell birth and death, including osteoclast and osteoblast turnover, contribute to the disease.

The disease reflects impaired bone homeostasis, with reduced bone mass arising from imbalance in bone remodeling. The literature grounding links osteoporosis to altered osteoclast and osteoblast genesis and apoptosis, changes in bone density, and regulatory effects of cytokines, hormones, and signal transduction pathways.

Female sex characteristics and the menopausal transition are supported risk factors through estrogen deficiency. Aging is also a major risk factor, and the grounding additionally points to diet and gastrointestinal microbiome-related factors as areas studied in relation to osteoporosis.

General management includes prevention, diagnosis, and therapy, with treatment described at the level of drug therapy and non-drug prevention and control. The grounding supports estrogen-based therapy as a relevant modality and broader osteoporosis treatment approaches aimed at preserving bone mass and reducing fracture risk.